Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 2 1Phase 1 1

Status

Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Carcinoma, Non-Small-Cell Lung 16Stomach Neoplasms 12Lung Neoplasms 9Adenocarcinoma 5Neoplasms 4Neoplasm Metastasis 4Esophageal Neoplasms 4Adenocarcinoma Of Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Urinary Bladder Neoplasms 1Thymoma 1Solid Tumors 1Solid Cancer 1Sarcoma 1Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Non-small Cell Lung Cancer Metastatic 1Neoplasms by Site 1Metastatic Small Intestinal Adenocarcinoma 1Metastatic Gastric Adenocarcinoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Head and Neck Neoplasms 1Gastrointestinal Neoplasms 1Fallopian Tube Neoplasms 1Digestive System Neoplasms 1Desmoplastic Small Round Cell Tumor 1

Interventions

Fluorouracil 16Oxaliplatin 14Nivolumab 14Leucovorin 13pembrolizumab 9Paclitaxel 9Capecitabine 9Radiotherapy 6Radiation 6durvalumab 5Taxes 5Irinotecan 5Cisplatin 5Trastuzumab 4Specimen Handling 4Drug Therapy 4Carboplatin 4tremelimumab 3dehydroftorafur 3Ramucirumab 3Magnetic Resonance Spectroscopy 3Folfox protocol 3Endoscopy 3Docetaxel 3Biopsy 3zimberelimab 2zanidatamab 2trastuzumab deruxtecan 2tislelizumab 2futibatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adenocarcinoma Of Esophagus × Ramucirumab × 1 year × Clear all
NCT06203600 2026-05-26

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
224 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT07594548 2026-05-18

Futibatinib With Paclitaxel and Ramucirumab for the Treatment of Locally Advanced or Unresectable Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma

Northwestern University

Phase 1 Not yet recruiting
18 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

NCT06251973 2026-05-15

A Study of agenT-797 in Combination With Botensilimab, Balstilimab, Ramucirumab, and Paclitaxel for People With Esophageal, Gastric, or Gastro-esophageal Junction Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Active not recruiting
20 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡